AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac Amyloidosis

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac Amyloidosis

Patent establishes IP across all major amyloidosis subtypes and transforms the standard 12-lead ECG into a screening tool for one of cardiology’s most underdiagnosed diseases

AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company's proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG.